2019
2694. Incidence of Pneumocytis jiroveci (PJP) Infection with 3-Month Prophylaxis of Aerosolized Pentamidine (AP) in Autologous Hematopoietic Stem Cell Transplantation (HSCT)
Perreault S, McManus D, Pulk R, Topal J, Foss F, Isufi I, Seropian S, Bar N. 2694. Incidence of Pneumocytis jiroveci (PJP) Infection with 3-Month Prophylaxis of Aerosolized Pentamidine (AP) in Autologous Hematopoietic Stem Cell Transplantation (HSCT). Open Forum Infectious Diseases 2019, 6: s947-s947. PMCID: PMC6809600, DOI: 10.1093/ofid/ofz360.2371.Peer-Reviewed Original ResearchAutologous hematopoietic stem cell transplantationHematopoietic stem cell transplantationPost-hematopoietic stem cell transplantationAutologous HSCT patientsAerosolized pentamidinePJP prophylaxisHSCT patientsPJP infectionYear post-hematopoietic stem cell transplantationYale-New Haven HospitalRisk of cytopeniaHigh-dose corticosteroidsStem cell transplantationNew Haven HospitalYears of ageCost of drugsAP prophylaxisDose corticosteroidsJiroveci infectionMonth regimenPrimary endpointRelapsed diseaseSecondary endpointsImmunomodulatory drugsRetrospective study
2009
Autologous and allogeneic transplantation for aggressive T-cell lymphomas: A single institution experience
Lansigan F, Cooper D, Seropian S, Foss F. Autologous and allogeneic transplantation for aggressive T-cell lymphomas: A single institution experience. Journal Of Clinical Oncology 2009, 27: 8558-8558. DOI: 10.1200/jco.2009.27.15_suppl.8558.Peer-Reviewed Original ResearchAggressive T-cell lymphomaProgression-free survivalT-cell lymphomaAuto groupFirst remissionBetter progression-free survivalAggressive B-cell lymphomasMedian prior therapiesNon-relapse mortalitySingle institution experienceRole of transplantationNon-Hodgkin lymphomaLarge cell transformationB-cell lymphomaAllo transplantPrior therapyRelapse mortalityRelapsed diseaseALLO groupPoor OSAllogeneic transplantationLymphoblastic lymphomaMedian ageMedian timeWorse prognosis